About CRISPR Therapeutics AG
CRISPR Therapeutics is a Swiss-American biotechnology company that engages in the development and commercialisation of gene-based therapies. Headquartered in Zug, Switzerland, it was founded in 2012 and also operates research and development facilities in Cambridge, Massachusetts. The company focuses on the fields of cancer treatment, blood disorders and diseases, regenerative medicine such as genetic engineering, and in vivo testing. CRISPR has partaken joint ventures with well-established industry names, such as Bayer and Vertex Pharmaceuticals. Its experimental treatment for sickle cell disease was notably the first CRISPR-based therapy to be approved on humans in the US. CRISPR Therapeutics stock is listed on the Nasdaq stock exchange. Start spread betting or trading CFDs on our CRISPR Therapeutics share price.
Why trade CRISPR Therapeutics AG with CMC Markets?
We've invested over £100m into our trading platform, creating pioneering technology that puts professional-grade grade software in your hands.
Set your default position size and enter with a single 'click'.
99.9% fill rate with 0.0029s execution*
Wherever possible we fill your trade and always at the price you see.
99.95%+ platform stability**
We consistently achieve core platform uptime, allowing you to focus on your trading.
We crunch 225m prices every day, from up to 14 feeds from tier one liquidity providers.